SITEMAP
- Home
-
Science
- Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
- Allergic Rhinitis
- Anti-Infectives
-
Asthma
-
Cutting Edge Science
- 2021
-
Innovation
- How does Dupixent help reduce asthma exacerbations across multiple phenotype
- What is your experience with Dupixent in your practice?
- Why is it important to measure FEV1 in patients with asthma?
- What beneficial impact does Dupixent have on OCS-Dependent patients?
- What feedback have you received from patients being treated with Dupixent?
- What gives you confidence that Dupixent improves patients’ quality of life?
- Managing Severe Asthma and CRSwNP through the lens of type 2 inflammation
- How does Dupixent target the underlaying type2 inflammation in asthma?
- Dupixent reduce Asthma Exacerbation across different type of patients
- How do you choose the right biologic for a particular asthma patients?
- When do you discuss biologic treatment with your asthma patients?
- What Challenges do you face when treating patients with Type 2 inflammation?
- How type 2 inflammation affect patients with Asthma?
- Why is it important to look for type 2 inflammation in patients with Asthma?
- How do you balance the cost of biologics with the value they can bring to patients?
- 2022
- 2023
-
Cutting Edge Science
- Atopic Dermatitis
-
Cardiovascular
-
Atherothrombosis
-
Cutting Edge Science
- Innovation
-
2022
- Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?
- Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice
- Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)
- Adherence and persistence analysis in patients treated with DAPT
- In hospital outcomes in young patients with AMI: Results from Gulf Coast
-
2023
- Clopidogrel vs Ticagrelor in ACS
- New Users of Ticagrelor / Clopidogrel Observational Study in Sweden
- Clopidogrel Based Strategies in ACS
- ESC 2021 - Dual Antiplatelet Therapy After Coronary Stenting in High Bleeding Risk Patients
- ESC 2021 - Antiplatelet therapy in high bleeding risk patients with or without OAC Therapy
- SMART-CHOICE Trial_P2Y12 Inhibitor Monotherapy in Complex PCI
- Clinical Outcome of Switching From Clopidogrel to Ticagrelor
- P2Y12 Inhibitor Adherence Trajectories in ACS
- Clopidogrel Monotherapy After Very Short DAPT
- DAPT De-Escalation Vs Standard DAPT
- Potent P2Y12 Inhibitors Vs Clopidogrel in Elderly ACS Patients
- Unguided De-Escalation from Ticagrelor to Clopidogrel
- De-escalation of DAPT for ACS
- Ticagrelor vs Clopidogrel in High Bleeding Risk Patients with ACS
- Net Clinical Benefit of Clopidogrel vs Ticagrelor
- DAPT for Secondary Prevention of AIS
- The SWITCH Study: Antiplatelet-Switching Strategy After Coronary Interventions
- P2Y12 Inhibitors After Coronary Stenting
- Clopidogrel vs Aspirin Post PCI Following DAPT
- De-Escalation to Clopidogrel in AMI
- P2Y12 Inhibitor Pre-Treatment in Patients with NSTE ACS
-
Cutting Edge Science
-
Dyslipidemia
-
Cutting Edge Science
-
2021
- NEJM Odyssey Outcomes
- ODYSSEY Outcomes
- Odyssey Outcomes - DM sub-analysis
- Odyssey Outcomes - Elderly Patients Results
- Odyssey Outcomes - CABG Results
- Odyssey Outcomes - PVD Results
- Odyssey Outcomes - Total Events Results
- Odyssey Outcomes - Mortality
- ESC/EAS 2019 International Guidelines
- Odyssey Outcomes - Total Events Analysis
- Effect of Alirocumab on MACE in patients with CKD
- Odyssey Outcomes - CVOT Mortality Sub-analysis
- Odyssey Outcomes - PVD Sub-analysis
- Italian real-world analysis for PCSK9 inhibitors new users
- Optimal use of LLT after ACS
- Real-life safety and efficacy of Alirocumab - ODYSSEY APPRISE study
- Regulate LDL-C level for those undergoing coronary revascularization (Diabetic Patients)
- Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress
- The ACTE Study
- The EXPLORER Study
- The ROSETTE Study
-
Innovation
- Treating to target in clinical practice: Why is it important to achieve recommended LDL-C levels?
- 2022
- Atherosclerosis: Identifying risks and improving outcomes
- Lipid Management in Patients with ACS/ASCVD
- Identifying and Treating Patients with High Lipidaemia Risk Post-ACS
- Improving Lipid Management for Patients Post-ACS
- Overview of Adherence Data with LLT Highlighting The Most Recent Data With PCSK9i
- Act Now for Your ACS Patients: Patient Identification
- Act Now for Your ACS Patients: Treat Aggressively, Combine and Start Early
- Act Now for Your ACS Patients: Optimise Your ACS Pathway
- Act Now for Your ACS Patients: Summary
- Metabolic Risk Factors and Effect of Alirocumab on CV Events
- Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)
- Managing the Recurrent ASCVD risk of your ACS Patient: A call to Action – GULF Perspective: Part 1
- Managing the Recurrent ASCVD risk of your ACS Patient: A call to Action – GULF Perspective: Part 2
- Managing the Recurrent ASCVD risk of your ACS Patient: A call to Action – GULF Perspective: Part 3
- Statin/ezetimibe SPC for better adherence to LLT
-
2022
- Prognostic impact of achieving LDL cholesterol guidelines
- PCSK9 inhibitors and ACS
- Clinical practice experience in patients with familial hypercholesterolemia (FH) from the SAFEHEART registry
- Perceptions and Barriers on the use of PCSK9 inhibitors
- The European experience: SWEDEHEART and AIFA registries
- Use of Lipid-Lowering Therapies Over 2 Years
- Evaluation of lipid management following ACS
- Lipid-Lowering Therapy and achievement of lipid targets ESC and EAS guidelines
- Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia
- LDL-C in the management of high cardiovascular risk, changing the paradigm for prevention
- Importance of lipid registries in cardiovascular prevention
- PCSK9i after hospital discharge for acute MI
- Why compromise for less: Should PCSK9 inhibitors be initial therapy?
- What do US physicians and patients think about LLTs and goals of treatment?
- Should we Encourage Earlier and Broader Use of Combination Therapies in Dyslipidemia?
- Role of Genetic Testing in Management of Dyslipidemia
- Recommendations for Residual Risk Reduction in ASCVD
- Atherosclerotic Cardiovascular Disease Risk Assessment
- Relationship Between LDL-C LLTs and Risk of Stroke
- Public health Recommendations for Lp(a) Measurement
- Possible Challenges Post One Year of ESC/EAS Guidelines
- LLTs Exposure Time and Major Vascular Risk Reduction
- PCSK9i and Prevention of CVD
- LDL-C Targets in Patients with HFH
- PCSK9 Inhibitors in Real World Practice
- LLTs and Antithrombotic Therapy in PAD
- Event Rates and Risk Factors for Recurrent CV Events
- ESC Lpa in Clinical Practice EAS Consensus Statement
- Statin/Ezetimibe Combination VS Statin Monotherapy
- CV Risk Management in T1DM Using Guidelines
- APSC Consensus Recommendations on Dyslipidemia
- LDL-C The Only Causal Risk Factor for ASCVD
- Achievement of ESC/EAS LDL-C Treatment Goals After an ACS with Statin and Alirocumab
- Single-Pill Combinations in Dyslipidemia
-
2023
- LLT and LDLC Over 2 years in CKD and ASCVD From the GOULD Registry
- 2022 ACC Expert Consensus on ASCVD Management
- Efficacy of PCSK9i on Lipid Residual Risk Lipid Real Registry
- Lp(a) Levels in Global ASCVD Patients
- Acute LDL-C Reduction Post ACS: Strike Early and Strike Strong: From Evidence to Clinical Practice
- Management of Patients With Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: 1-year Outcomes of The PERI-DYS Study
- Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia (ACOSYM Study)
- Meta Analysis of apoB Lowering and CV Risk
- Hypercholesterolemia Treatment Patterns and Lipid Target in ACS Patients
-
2021
-
Cutting Edge Science
- Hypertension
-
Thrombosis
-
Cutting Edge Science
-
2021
- GAPS trial: Low-dose LMWH and GCS in in elective surgical inpatients at moderate or high risk VTE
- Enoxaparin monotherapy vs UFH monotherapy among inpatients with NSTEMI
- Acute Medical Illness: Advanced Age Alone Predicts Venous Thromboembolism Similar to Existing Risk Assessment Models
- VTE prophylaxis in surgical patients
- Incident heart failure tied to increased long-term risk for VTE
- VTE incidence after cesarean delivery
- ASH 2019 Guidelines for Surgical Prophylaxis
- VTE prophylaxis in medically ill patients
- Unmet clinical needs in the management of VTE in at-risk patients
- Risk for VTE is higher in emergency surgery than elective procedures
- Duration of thromboprophylaxis following major abdominopelvic cancer-related surgery
- Risk factors of lower extremity DVT in patients undergone gynecological laparoscopic surgery
- Safety of preoperative LMWH in lung cancer patients
- Impact of anemia on long-term clinical outcomes in VTE
-
2022
- Evaluation of comparative efficacy and safety of thromboprophylaxis agents among critically ill patients
- 2019 ESC Guidelines for Acute Pulmonary Embolism
- Risk for Post-operative Venous Thromboembolism in Patients Receiving Enoxaparin Prophylaxis
- Changing trends in VTE: Pulmonary Embolism Cases on Rise within the Last Decade
- Utility of Pregnancy-Adapted YEARS Algorithm in Diagnosis of Pulmonary Embolism
- VTE Comparison of Pregnancy-Specific Risk Scoring Systems in Hospitalized Maternity Patients
- Risk for pulmonary embolism continues beyond 6 weeks of surgery
- Trends in Pulmonary Embolism-related mortality in Europe
- Prolonged Thromboprophylaxis with LMWH after Abdominal or Pelvic Surgery
- Independent Risk Factors for Venous Thromboembolism
- Specific Patient Characteristics Linked to Below Average Quality of Life in Patients with Recent VTE
- Benefit of Prophylaxis for Your High-Risk Surgical Patient
- Thematic Review on Perioperative Venous Thromboembolism Prophylaxis
- Global Use of RAM and Thromboprophylaxis in Hospitalized Patients
- Major GI Bleeding in VTE RIETE Analysis
- Caprini Score Responses to Prevent VTE in Patients Undergoing Varicose Vein Surgery
- Maternity Clot Risk Model to Predict Women at Risk of VTE
- Innovation
-
2023
- Post Thrombotic Syndrome in Women
- DVT in Post-partum Case of Caesarean Section
- VTE Incidence after Cesarean Delivery in Selected Guidelines
- Low risk of VTE Following Early Pregnancy Loss in Pregnancies Conceived by IVF
- Maternal and Perinatal Outcomes of VTE
- Recurrence of VTE in Patients with Recent Gestational DVT or PE
-
2021
-
Cutting Edge Science
- Cutting Edge Science
-
Atherothrombosis
- Chronic Obstructive Pulmonary Disease
-
Diabetes
-
Cutting Edge Science
- 2021
-
Innovation
- Diabetes Your Type: Testimonial by Dr. Hussein
- Diabetes Your Type: Testimonial by Dr. Bassam
- T1DM Mini-Series: How to Avoid Hypoglycaemia in People with T1 Diabetes?
- Edition Junior Study - Helping patients with type 1 diabetes (T1D) to find better treatment options
- 2022
- InRange Study
- ATTD 2021: Technology supporting initiation, titration and intensification
- ATTD 2021: Patients’ profiles for digital tools
- Summary of SAGE study on Adults with T1DM
- Do historical HbA1c values explain glycemic legacy effect of type 2 diabetes?
- Is Premixed insulin an effective treatment for type 2 diabetes uncontrolled by OADs?
- Gulf sub-group analysis of the real-world Orion study
- The SoliRam observational study
- Insulin advancement in Type 2 diabetes: Unmet needs with commonly-used options
- Treatment simplification of complex insulin regimens in T2D
- Advancing Therapy with iGlarLixi: Differentiation from other complex regimens
- Advancing Therapy with iGlarLixi: Differentiation from complex insulin regimens
- Challenges associated with commonly-used insulin advancement options
- EVOLUTION: RWE from Saudi Arabia
- TITRATION INERTIA; A Predominant Issue for People with Diabetes
- The burden associated with insulin self-management
- Glargine 300 use in people with type 2 diabetes who fast during Ramadan
- ADA Modules
-
2022
- Real-World Safety and Effectiveness of iGlarLixi in People with Type 2 Diabetes who Fast During Ramadan
- Attainment of Goals in Type 2 Diabetes
- Diabetes Management During Ramadan
- Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes (Solimix)
- Management of athletes and active people with diabetes
- Single injectable treatment may not be enough to get T2DM patient to glycemic goal
- A narrative review for clinicians on insulin management for T2DM during Ramadan
- Closed-loop insulin delivery during exercise in people with T1D
- Recommendations on treatment simplification of complex insulin regimens to improve clinical outcomes in patients with T2DM
- Post-exercise hypoglycemia in relation to medication regimen among adults with type 2 diabetes
- 2023
- 2024
-
Cutting Edge Science
- Eosinophilic Esophagitis
- Microbiota and Probiotics
-
Multiple Myeloma
-
Multiple Sclerosis
-
Cutting Edge Science
- Innovation
-
2022
- Thalamic atrophy as a new biomarker of MS? The predictive value and how to use in clinical practice
- A promising biomarker in MS: Neurofilament light chain
- How old is your brain?
- Cognitive training – a curse or a blessing?
- The reason for MS – beyond focal inflammation
- Measuring brain atrophy. What can be done and where are we heading?
- Exercise as ”medicine” in the treatment of MS
- Cognitive decline – the invisible burden of MS?
- Falling chronically ill – How do I cope and move forward?
- The importance of Deep Grey matter in MS
- Why has our brain suddenly become of interest?
- MS Newsletter
-
2023
- Efficacy And Safety Of Switching To Teriflunomide In Older Patients With Relapsing Multiple Sclerosis
- Real-world Study on Teriflunomide in Relapsing-remitting Multiple Sclerosis Patients from the Nordic Countries
- Pregnancy Outcomes Following Maternal or Paternal Exposure to Teriflunomide
- Influence Of Pregnancy On Multiple Sclerosis And Disease-modifying Therapies And Vice Versa
- Real-world Efficacy and Safety of Teriflunomide in Multiple Sclerosis: an Expert Consensus for GCC
- Meet Sanofi MS Specialists
-
Cutting Edge Science
-
Nasal Polyps
-
Cutting Edge Science
- 2021
- 2022
-
2023
- When DUPIXENT is available, I would say go for it
- What can biologic treatment do for patients with CRS with nasal polyps?
- How does DUPIXENT help recover smell?
- How do you factor safety into treating patients with CRSwNP?
- "It really has changed the way I manage our patients"
- “Smell—we call it the Cinderella of the senses"
- What does patient empowerment mean for your treatment plan?
- Compelling trial results: CRS with nasal polyps
- You can imagine more than 90% of CRSwNP Patients losses their ability's of smell
- IL4/IL13 are the central cytokines for type 2 inflammation in CRSwNP
- NPS improvement with Dupixent over time
- Hear From An Expert On What Is The Underlying Cause Of Crs With Nasal Polyps?
- Rethink Your Nasal Polyps. Type 2 Inflammation A Nasal Polyp Mystery
- Hear From An Expert On How Can You Limit The Effects Of Systemic Steroid Use For Patients With Crs With Nasal Polyps?
- Hear From An Expert On What Are The Main Challenges In Treating Patients With Crs With Nasal Polyps?
- Hear From An Expert On Identify Patients Who Are Appropriate Candidates For Biologic Treatment
- Hear From An Expert On How Do You Manage Treatment Compliance Issues In Patients With Crs With Nasal Polyps?
- Hear From An Expert On How Do You Address Patients' Concerns About Sinus Surgery?
- Hear From An Expert On Would You Consider A Biologic For A Surgery-Naïve Patient With Crs With Nasal Polyps?
- Hear From An Expert On How Does Dupixent Target Underlying Type 2 Inflammation?
- Hear From An Expert On What Does Dupixent Bring To Your Practice?
- Hear From An Expert On The Type 2 Immune Response And Inflammation
- Pneumology Meets Oto-Rhino-Laryngology: A Discussion of Type 2 Inflammation in Airway Diseases
- Hear From An Expert On What Does The Future Of Treatment Look Like For Crs With Nasal Polyps?
- Hear From An Expert On What Have You Learned From Your Experience With Biologics?
- Expert Opinions: Would You Consider A Biologic For A Crswnp Patient Who Has Had Sinus Surgery?
-
Cutting Edge Science
- Neurological Disorders
- Prurigo Nodularis
- Transplant
- Vaccines
-
Rare Diseases
-
Cutting Edge Science
- 2021
-
Innovation
- Lysosomal Storage Diseases from Neurology Perspective
- 2022
- Their Stories shaped them like Pearls
- Early diagnosis and management of IOPD
- Diagnostic challenges of LOPD
- Living with Pompe Disease series is live on Youtube Juan's story
- Professor Moeen Al Sayed video on ASMD
- Professor Tawfeq Ben Omran video on ASMD
- Professor Fatma Al-Jasmi video on ASMD
- Diagnostic Algorithm for Gaucher Disease in Adult
- Bone Monitoring Guidelines in Gaucher Disease Video
- Diagnostic Algorithm for Gaucher Disease in Pediatric
- Pompe don’t lose time video
- Gaucher disease awareness month video
- How To Diagnose LSDs?
- Better care for Fabry
- 2022
-
2023
- MPSI
- Fabry
- Pompe
- Literature Analysis on LOPD Symptoms (Pulmonology)
- Literature Analysis on LOPD Symptoms (Rheumatology)
- EXPERT GROUP CONSENSUS FROM THE ARABIAN PENINSULA ON THE DIAGNOSIS OF LOPD
- Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease for orthopedists
- PREVALENCE OF LOPD IN PATIENTS WITH UNDIFFERENTIATED PROXIMAL MYOPATHY AND UNDIAGNOSED MUSCLE BIOPSY
- EXPERT GROUP CONSENSUS FROM THE ARABIAN PENINSULA ON THE DIAGNOSIS OF LOPD GPsPedsIM
- DIFFERENTIAL DIAGNOSIS OF LOPD AND MYOTONIC DYSTROPHY TYPE 1 THROUGH ABDOMINAL ULTRASONOGRAPHY-2
- Gaucher
- An overview of Lysosomal Storage Disorders & Sanofi`s Commitment to the Development and Provision of Treatments
- 2024
- Meet Sanofi Specialist
-
Cutting Edge Science
-
Patient Support
- Patient Support Articles
- Allergic Rhinitis
- Atopic Dermatitis
- Cardiovascular
-
Diabetes
- 2021
- Innovation
-
Tools And Resources
- My Dose Coach
- My Dose Coach - Self Titration
- My Dose Coach - About MDC
- My Dose Coach - Real World Evidence
- My Dose Coach - Getting Started
- My Dose Coach - Patient Guide
- My Dose Coach - Register your Clinic
- Pre-Ramadan assessment and Risk calculation for diabetic patients during Ramadan
- Clinical and economic value of SOLIQUA - Pharmacist perspective
- 2022
- Contact Sanofi Medical Liaison
- Nasal Polyps
- Rare Diseases
-
Events
-
Cardiovascular
-
2021
- Dyslipidemia Webinar
- VTE Safety Zone: Assessing the VTE Risk in Hospital and Beyond
- VTE Safety Zone: The Role of Thromboprophylaxis for the Prevention of VTE
- Dyslipidemia Expert Exchange: Best practice approaches in dyslipidemia management
- VTE Safety Zone: VTE in general surgery from risk assessment to appropriate thromboprophylaxis
- VTE Safety Zone: Prof. Juan Arcelus - Primary VTE Prophylaxis in Patients with Cancer Undergoing Major Abdominal/Pelvic Surgery
- VTE Safety Zone: Primary VTE Prophylaxis in Patients with Cancer Undergoing Major Abdominal/Pelvic Surgery
-
2022
- Dyslipidemia Webisodes: Mortality data with Prof. Tunon
- Hypertension - The Most Important Disease in Medicine II
- Hypertension - The Most Important Disease in Medicine
- Sanofi Thrombosis Summit
- Venous Thromboembolism Burden
- Venous Thromboembolism in Acutely Medically Ill Patients
- Challenges of VTE Prophylaxis in Surgery
- 2023
-
2021
-
Diabetes
- 2021
-
2022
- Nutrition and Insulin management in Ramadan
- Diabetes Guidelines in Ramadan
- Type 2 Diabetes Cost Effective Management
- Navigate new destinations in diabetes management
- Dia-Tour Inquiry Form
- Leveraging Time-In-Range to Improve The Patient Experience Video (Prof. Robert Ritzel)
- The Role of Basal Insulin in Type 2 Diabetes Webinar
- Ultimate Need for Intensification
- Innovation of Iglarlexi in Intensification
- Innovation in Simplification Vs Basal Boulus
-
2023
- Safe & Smart: Cardio Safe & Gluco Smart Approach in Diabetes Management
- GAED 2023
- Cardiometabolic Approach in Diabetes Management
- Treating Type 2 Diabetes Today - How is it Changing?
- Safe & Smart - Dr. Salah
- Safe & Smart - Dr. Nabil
- Safe & Smart - Dr. Khudhair
- Safe & Smart - Dr. Kalra
- World Diabetes Day
- Rare Disease
- Vaccines
-
Multiple Sclerosis
- 2022
-
2023
- KSUMC Aubagio experience
- Magnetization Transfer Ratio Reduction
- Aubagio real world experience
- Pathology of chronic Smouldering MS SKMC Experiences - Dr.Mustafa Shakra
- A Patient's Journey on Teriflunomide: insights into Long-Term Treatment
- MSXChange l MS and Women
- The Underlying Biology of Neuroinflammation
- Prurigo Nodularis
- Neurological Disorders
- Anti Infectives
- Allergic Rhinitis
- Zympass Launch Right
- Zympass Launch Right
-
Cardiovascular
- Search
- Registration
- Login
- Products